ClinicalTrials.gg
CompletedNCT03067376Updated Aug 9, 2019

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

A Phase 1 interventional study of [14C]-CORT125134 in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-09.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
All
01

Study summary

The study was designed to evaluate how CORT125134 is taken up, broken down and removed from the body when given as an oral capsule to healthy subjects.

Read the detailed description

The study was conducted to determine the recovery of [14C]-CORT125134 after the administration of a single oral dose of [14C]-CORT125134, to determine the routes and rate of elimination of [14C]-CORT125134 and associated radioactivity from the body, and to measure concentrations of radioactivity in the blood. Additional objectives of the study were to determine the chemical structure of each significant metabolite in plasma, urine and feces. Safety and tolerability were assessed.

02

Conditions studied

  • Healthy

Keywords

  • Absorption, distribution, metabolism, and excretion (ADME)
  • Metabolism
  • Metabolite Profiling
  • Excretion
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or healthy females of non- (surgically sterilized or [defined as a woman of with at least a 12 month history of amenorrhea with a follicle-stimulating hormone (FSH) >40 international units per liter (IU/L) in the absence of a reversible medical iatrogenic cause])
  • Age 30 to 65 years of age
  • A history of regular bowel movements (averaging ≥1 and ≤3 stools per day)
  • Must be willing and able to communicate and participate in the whole study
  • Must provide written
  • Male participants must agree to use an adequate method of
  • Participants are willing to abide by the study restrictions

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical research study within the previous 3 months
  • Participants who have previously been enrolled in this study or participants who have previously been treated with CORT125134
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 milliliter (mL) of 40% spirit or a 125 mL glass of wine)
  • Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 parts per million (ppm)
  • Females of (female participants must have a negative urine pregnancy test)
  • Male Participants with pregnant partners
  • Radiation exposure exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. The measurement includes exposure from the present study, and diagnostic x rays and other medical exposures, but excludes background radiation. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999.
  • Positive drugs of abuse test result
  • Participants who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 grams per day paracetamol) or herbal remedies in the 14 days before study drug administration. Hormone replacement therapy is not permitted
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    [14C]-CORT125134

    Two capsules each containing 125 milligrams (mg) \[14C\]-CORT125134 administered to each participant on 1 occasion

    Drug: [14C]-CORT125134

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of radioactivity eliminated in urine

    Time frame: Day 1 pre-dose to Day 8 post-dose

  2. Amount of radioactivity eliminated in feces

    Time frame: Day 1 pre-dose to Day 8 post-dose

  3. Amount of radioactivity eliminated in urine and feces

    Time frame: Day 1 pre-dose to Day 8 post-dose

  4. Cumulative amount of radioactivity eliminated in urine

    Time frame: Day 1 pre-dose to Day 8 post-dose

  5. Cumulative amount of radioactivity eliminated in feces

    Time frame: Day 1 pre-dose to Day 8 post-dose

  6. Cumulative amount of radioactivity eliminated in urine and feces

    Time frame: Day 1 pre-dose to Day 8 post-dose

  7. Pharmacokinetics (PK) of total radioactivity: lag time (tlag)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  8. PK of total radioactivity: peak plasma concentration (Cmax)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  9. PK of total radioactivity: time to reach maximum observed concentration (tmax)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  10. PK of total radioactivity: area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  11. PK of total radioactivity: area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  12. PK of total radioactivity: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total AUC (%AUCextrap)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  13. PK of total radioactivity: first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve (lambda-z)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  14. PK of total radioactivity: elimination half-life (t1/2)

    Time frame: Day 1 pre-dose to Day 8 post-dose

  15. Metabolic profiling and structural identification in plasma, urine and feces

    Time frame: Day 1 pre-dose to Day 8 post-dose

Secondary outcomes

  1. Hematology

    Time frame: Screening, Day 1 pre-dose, Day 8

  2. Clinical chemistry

    Time frame: Screening, Day 1 pre-dose, Day 8

  3. Urinalysis

    Time frame: Screening, Day 1 pre-dose, Day 8

  4. Blood pressure

    Time frame: Screening, Day 1 pre-dose and 2 hours post-dose, Day 8

  5. Heart rate

    Time frame: Screening, Day 1 pre-dose and 2 hours post-dose, Day 8

  6. Electrocardiogram

    Time frame: Screening, Day 1 pre-dose and 2 hours post-dose, Day 8

  7. Percentage of subjects with adverse events

    Time frame: Screening to Day 28

  8. Physical examination

    Time frame: Screening and Day 8

  9. Tlag of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  10. Cmax of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  11. Tmax of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  12. AUClast of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  13. %AUCextrap of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  14. AUCinf of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  15. Lambda-z of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  16. T1/2 of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  17. Mean Residence Time (MRT) of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  18. Apparent oral clearance (CL/F) of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  19. Apparent volume of distribution (Vz/F) of CORT125134

    Time frame: Day 1 pre-dose to Day 8 post-dose

  20. Number of metabolites >10% of circulating radioactivity in plasma

    Time frame: Day 1 pre-dose to Day 8 post-dose

  21. Number of metabolites >10% of the dose in urine

    Time frame: Day 1 pre-dose to Day 8 post-dose

  22. Number of metabolites >10% of the dose in feces

    Time frame: Day 1 pre-dose to Day 8 post-dose

07

Study locations

1 site
  • Quotient Clinical
    Nottingham, Nottinghamshire NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2016
First posted
Mar 1, 2017
Start
Aug 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Last update
Aug 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03067376
Responsible party
Sponsor
First posted
Mar 1, 2017
Start date
Aug 2016
Primary completion
Sep 2016
Completion
Sep 2016
Last update
Aug 9, 2019

Study contacts

Pui Leung, MBChB
principal investigator · Quotient Clinical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion